Your browser doesn't support javascript.
loading
Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study.
Feliu, Jaime; Jiménez-Munárriz, Beatriz; Basterretxea, Laura; Paredero, Irene; Llabrés, Elisenda; Antonio-Rebollo, Maite; Losada, Beatriz; Espinosa, Enrique; Gironés, Regina; Custodio, Ana Belén; Del Mar Muñoz, María; Díaz-Almirón, Mariana; Gómez-Mediavilla, Jeniffer; Pinto, Alvaro; Torregrosa, María-Dolores; Soler, Gema; Cruz, Patricia; Higuera, Oliver; Molina-Garrido, María José.
Afiliação
  • Feliu J; Oncology Department, Hospital Universitario La Paz, Cátedra UAM-AMGEN, CIBERONC, Madrid, Spain.
  • Jiménez-Munárriz B; Oncology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain.
  • Basterretxea L; Oncology Department, ESI/OSI Donostialdea, Donostialdea, Spain.
  • Paredero I; Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain.
  • Llabrés E; Oncology Department, Hospital Universitario Insular de Gran Canarias, Las Palmas, Spain.
  • Antonio-Rebollo M; Oncohematogeriatrics Unit, Institut Català d'Oncologia, IDIBELL Hospitalet, Barcelona, Spain.
  • Losada B; Oncology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
  • Espinosa E; Oncology Department, Hospital Universitario La Paz, Cátedra UAM-AMGEN, CIBERONC, Madrid, Spain.
  • Gironés R; Oncology Department, Hospital Lluis Alcanyis de Xátiva, Valencia, Spain.
  • Custodio AB; Oncology Department, Hospital Universitario La Paz, Cátedra UAM-AMGEN, CIBERONC, Madrid, Spain.
  • Del Mar Muñoz M; Oncology Department, Hospital Virgen de la Luz, Cuenca, Spain.
  • Díaz-Almirón M; Biostatistics Department, Hospital La Paz, Universidad Autónoma de Madrid, Madrid, Spain.
  • Gómez-Mediavilla J; Oncology Department, ESI/OSI Donostialdea, Donostialdea, Spain.
  • Pinto A; Oncology Department, Hospital Universitario La Paz, Cátedra UAM-AMGEN, CIBERONC, Madrid, Spain.
  • Torregrosa MD; Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain.
  • Soler G; Oncohematogeriatrics Unit, Institut Català d'Oncologia, IDIBELL Hospitalet, Barcelona, Spain.
  • Cruz P; Oncology Department, Hospital Universitario La Paz, Cátedra UAM-AMGEN, CIBERONC, Madrid, Spain.
  • Higuera O; Oncology Department, Hospital Universitario La Paz, Cátedra UAM-AMGEN, CIBERONC, Madrid, Spain.
  • Molina-Garrido MJ; Oncology Department, Hospital Virgen de la Luz, Cuenca, Spain.
Oncologist ; 25(10): e1516-e1524, 2020 10.
Article em En | MEDLINE | ID: mdl-32329131
ABSTRACT

BACKGROUND:

Standard oncology tools are inadequate to distinguish which older patients are at higher risk of developing chemotherapy-related complications. MATERIALS AND

METHODS:

Patients over 70 years of age starting new chemotherapy regimens were prospectively included in a multicenter study. A prechemotherapy assessment that included sociodemographics, tumor/treatment variables, and geriatric assessment variables was performed. Association between these factors and the development of grade 3-5 toxicity was examined by using logistic regression.

RESULTS:

A total of 551 patients were accrued. Chemotherapy doses (odds ratio [OR] 1.834; 95% confidence interval [CI] 1.237-2.719) and creatinine clearance (OR 0.989; 95% CI 0.981-0.997) were the only factors independently associated with toxicity. Only 19% of patients who received reduced doses of chemotherapy and had a creatinine clearance ≥40 mL/minute had grade 3-4 toxicity, compared with 38% of those who received standard doses or had a creatinine clearance <40 mL/minute (p < .0001). However, no satisfactory multivariate model was obtained using different selection approaches.

CONCLUSION:

Chemotherapy doses and renal function were identified as the major risk factors for developing severe toxicity in the older patient. These factors should be considered when planning to initiate a new chemotherapy regimen and should also lead to a closer follow-up in these patients. IMPLICATIONS FOR PRACTICE Older patients are more vulnerable to chemotherapy toxicity. However, standard tools are inadequate to identify who is at higher risk of developing chemotherapy-related complications. Chemotherapy doses (standard vs. reduced) and renal function were identified as the major risk factors for developing severe toxicity in the elderly. These factors should be considered when planning to initiate a new chemotherapy regimen and should also lead to a closer follow-up.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha